And so that’s been great. So both the clinical benefit and the practice economics benefit are front and center in those conversations. And then after we get buy-in, we had, there are demos, onsite demos that are done and contracts are negotiated. And then there is an integration process that we’re €“ that we’re working to streamline that require our team to come in and make sure that the system is runs properly on their IT system and is fully integrated as well as training and the process by which patients our are on-boarded. So, that’s the ground process, again, we’re in the early stages, but it’s working well. We’re continuing to fine tune it, to streamline it, to make it more efficient and more and more cost effective over time. Once we get the implantable device, it’ll €“ it won’t change the fundamentals dramatically in that, it’ll remain that the €“ it’ll remain heavily focused on enhancing care as well as on remote patient monitoring and the impact of that on a practice.
But it’ll obviously supercharge that in some way because the implantable provides more sophisticated data as well as guaranteed a 100% patient compliance. We will need at that point to start engaging with the folks who implant these devices, typically interventional radiologists or vascular surgeons to train them and to get them to bring them into the loop. And that’s something we’ll start doing as we head €“ as we get closer to a commercial implantable device.
Frank Takkinen: Okay. That’s helpful. And then maybe just a follow up. I think you actually answered it in the previous question, but I want to confirm I heard it correct. The rev share portion that Veris receives was 80 to 100 per patient per month?
Lishan Aklog: Correct.
Frank Takkinen: And two, does the €“ okay. And then does the model change once you have the implantable? Is there any upfront sale of the implantable or
Lishan Aklog: Yes, great question. We haven’t finalized how we’re going to do that. There is an opportunity, generally the implantable port of business is fairly commoditized with regard to pricing. But there are going to be opportunities to because of the €“ because of its impact on the broader business model to craft customized strategies around that. We’re not likely to provide it for free, and we think, we’ll be able to make additional revenue on that, but we, because it is part of a value-added system that we’ll be able to really, we like to say actually that €“ we have the opportunity here to shake up not just the cancer care part of this, but actually the vast report aspect of this as well, which has been decades of essentially the same technology without any smart features.
And being able to provide that with appropriate economics, because of the value-added aspects of it’s going to be exciting, but we haven’t finalized that yet, Frank, that’s great question.
Frank Takkinen: Okay. Got it. And then this last one, and I think this was like, was covered on the call yesterday, but I think it might be worth mentioning again. Test volume growth and Lucid continues to be really solid. Sounds like you’re doing some retroactive billing now. Maybe just talk to any RevRec you’ve experienced in 2023 at those higher reimbursement levels so far, and expectations going forward for RevRec now you’re starting to get those in place?
